ArticleNeurogastroenterology and motility2011
Colonic butyrate- algesic or analgesic?
Article in Neurogastroenterology and motility, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance.Alimentary pharmacology & therapeutics · 2026Trial
- Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.Neurogastroenterology and motility · 2020Trial
- Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications.Life (Basel, Switzerland) · 2024Review
- The Role of the FODMAP Diet in IBS.Nutrients · 2024Review
- New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics.Journal of gastroenterology · 2023Review
- Bibliometric and visual analysis of research on the links between the gut microbiota and pain from 2002 to 2021.Frontiers in medicine · 2022Article
- Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components.Journal of personalized medicine · 2021Article
- Corrigendum: Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier.Frontiers in nutrition · 2021Article
- Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier.Frontiers in nutrition · 2021Review
- Short chain fatty acids and monocarboxylate transporters in irritable bowel syndrome.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment.International journal of molecular sciences · 2020Review
- Microbial and metabolomic profiles in correlation with depression and anxiety co-morbidities in diarrhoea-predominant IBS patients.BMC microbiology · 2020Article
- Microbiota-neuroimmune cross talk in stress-induced visceral hypersensitivity of the bowel.American journal of physiology. Gastrointestinal and liver physiology · 2020Article
- Microbiota: a novel regulator of pain.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome.Scientific reports · 2019Article
- Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats.Journal of gastroenterology and hepatology · 2019Article
- Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study.Behavioral sciences (Basel, Switzerland) · 2018Article
- Metabolites and microbial composition of stool of women with fecal incontinence: Study design and methods.Neurourology and urodynamics · 2018Article
- Fructo-oligosaccharide intensifies visceral hypersensitivity and intestinal inflammation in a stress-induced irritable bowel syndrome mouse model.World journal of gastroenterology · 2017Article
- Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.American journal of physiology. Gastrointestinal and liver physiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Irritable bowel syndrome (IBS) is a common health issue that is characterized by abdominal pain, abnormal bowel movements, and altered visceral perception. The complexity and variability in symptoms pose serious challenges in treating IBS. Current therapy for IBS is primarily focused on reducing the abdominal pain, thereby improving the quality of life to a significant extent. Although the use of fiber rich diet is widely recommended in treating IBS, some studies have questioned its use. Intra-colonic butyrate, a short-chain fatty acid, is primarily produced by the fermentation of dietary fibers in the colon. In the existing literature there are conflicting reports about the function of butyrate. In rats it is known to induce visceral hypersensitivity without altered pathology, whereas in humans it has been reported to reduce visceral pain. Understanding the molecular mechanisms responsible for this contrasting effect of butyrate is important before recommending fiber rich diet to IBS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.